Genfit SA (GNFT)
After hours:
| Previous close | 4.5300 |
| Open | 4.5100 |
| Bid | 4.0000 x 2200 |
| Ask | 4.8700 x 1000 |
| Day's range | 4.4200 - 4.5450 |
| 52-week range | 3.0100 - 7.1900 |
| Volume | |
| Avg. volume | 733,233 |
| Market cap | 222.278M |
| Beta (5Y monthly) | 1.26 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Can GENFIT S.A. Unsponsored ADR (GNFT) Climb 79% to Reach the Level Wall Street Analysts Expect?
The consensus price target hints at a 78.9% upside potential for GENFIT S.A. Unsponsored ADR (GNFT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- Zacks
How Much Upside is Left in GENFIT S.A. Unsponsored ADR (GNFT)? Wall Street Analysts Think 60%
The mean of analysts' price targets for GENFIT S.A. Unsponsored ADR (GNFT) points to a 59.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- Motley Fool
Why Genfit Stock Is Skyrocketing Today
What happened Shares of Genfit (NASDAQ: GNFT) were skyrocketing 25% higher at 11:58 a.m. EST on Wednesday. The big jump came after the company announced positive results from a phase 2 study evaluating elafibranor in treating primary biliary cholangitis (PBC), an autoimmune disease that causes scarring of bile ducts in the liver.
